Latest Content
Feb 23 - 2024
Antibody-drug conjugates (ADCs) are the hottest real estate in oncology, attracting billions from big pharma:
Pfizer acquired Seagen for $43 billion
AbbVie invested over $10 billion in ImmunoGen
Merck committed $4 billion upfront, with a potential total...
Read More
Feb 12 - 2024
In 2023, the digital health ecosystem witnessed notable consolidation, increased investor scrutiny and a decline in investor support. Health systems prioritised operational efficiency and big tech made strategic investments in emerging AI capabilities.
This...
Read More
Feb 01 - 2024
Most in the biopharma industry would prefer to leave 2023 in the rearview mirror. Before we forge ahead, though, it’s valuable to reflect on how this challenging year closed out.
Our 2023 Review covers the good, the bad and the ugly as we ask: Has the...
Read More
No posts found
More content
Loading...